[go: up one dir, main page]

PE20061154A1 - Composiciones farmaceuticas inyectables estabilizadas con particulados de posaconazol - Google Patents

Composiciones farmaceuticas inyectables estabilizadas con particulados de posaconazol

Info

Publication number
PE20061154A1
PE20061154A1 PE2005001463A PE2005001463A PE20061154A1 PE 20061154 A1 PE20061154 A1 PE 20061154A1 PE 2005001463 A PE2005001463 A PE 2005001463A PE 2005001463 A PE2005001463 A PE 2005001463A PE 20061154 A1 PE20061154 A1 PE 20061154A1
Authority
PE
Peru
Prior art keywords
posaconazole
formulation
particulates
pharmaceutical compositions
injectable pharmaceutical
Prior art date
Application number
PE2005001463A
Other languages
English (en)
Inventor
Leonore Witchey-Lakshmanan
Sydney Ugwu
Varda Sandweiss
Roberta S Hare
Zaiqi Wang
Marco Taglietti
Gopal Krishna
Catherine Hardalo
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20061154A1 publication Critical patent/PE20061154A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UNA FORMULACION QUE COMPRENDE UNA SUSPENSION DE POSACONAZOL ESTABILIZADA POR UN FOSFOLIPIDO TAL COMO 1-PALMITOIL-2-OLEOIL-SN-GLICEROL-3-FOSFOCOLINA (POPC), EN UNA MEZCLA QUE COMPRENDE AGUA, UN TERMOPROTECTOR TAL COMO TREHALOSA Y UN SISTEMA DE AMORTIGUADOR, DONDE DICHA FORMULACION NO TIENE MAS QUE UN 50% EN VOLUMEN DE PARTICULAS CON UN TAMANO DE UN MICRON O MENOS. EL POSACONAZOL TIENE UNA DISTRIBUCION DE TAMANO DE PARTICULA CON UN VALOR MEDIO DE TAMANO DE PARTICULA ENTRE 1.5 Y 3.0 MICRONES QUE SE MANTIENE DESPUES DE SER ESTERILIZADAS TERMINALMENTE POR PROCESO DE AUTOCLAVE A 121°C DURANTE HASTA 150 MINUTOS. DICHA FORMULACION ES UTIL EN EL TRATAMIENTO DE INFECCIONES TALES COMO CANDIDIASIS, FUSARIOSIS, LEISHMANIASIS, INFECCIONES DEBIDO A HONGOS DIMORFICOS, ENTRE OTRAS
PE2005001463A 2005-05-27 2005-12-14 Composiciones farmaceuticas inyectables estabilizadas con particulados de posaconazol PE20061154A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/140,294 US20060009469A1 (en) 2004-05-28 2005-05-27 Particulate-stabilized injectable pharmacutical compositions of posaconazole

Publications (1)

Publication Number Publication Date
PE20061154A1 true PE20061154A1 (es) 2006-11-09

Family

ID=36354136

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005001463A PE20061154A1 (es) 2005-05-27 2005-12-14 Composiciones farmaceuticas inyectables estabilizadas con particulados de posaconazol

Country Status (5)

Country Link
US (1) US20060009469A1 (es)
AR (1) AR052162A1 (es)
PE (1) PE20061154A1 (es)
TW (1) TW200640459A (es)
WO (1) WO2006130177A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070281011A1 (en) * 2006-05-30 2007-12-06 Elan Pharma International Ltd. Nanoparticulate posaconazole formulations
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
EP2130540A1 (en) * 2008-06-02 2009-12-09 Sandoz AG Pharmaceutical compositions containing a crystalline form of posaconazole
WO2009157009A1 (en) * 2008-06-25 2009-12-30 Akums Drugs And Pharmaceuticals Limited An intravenous drug delivery system
EP2555828B1 (en) * 2010-04-09 2017-07-19 Unilever PLC, a company registered in England and Wales under company no. 41424 Oral care compositions
CN107049935A (zh) * 2010-06-29 2017-08-18 默沙东公司 取代β‑环糊精稳定的泊沙康唑静脉输注液制剂
JP5341059B2 (ja) 2010-11-09 2013-11-13 株式会社大塚製薬工場 幹細胞懸濁液
DK3702374T3 (da) 2012-02-15 2022-06-27 Cydex Pharmaceuticals Inc Fremsgangsmåde til fremstilling for cyclodextrin-derivater
KR20160033795A (ko) 2012-02-28 2016-03-28 사이덱스 파마슈티칼스, 인크. 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법
CN103664622B (zh) * 2012-09-18 2016-01-13 浙江工业大学 Ab型羟基改性高聚物的单体及其中间体和制备方法
WO2014066274A1 (en) 2012-10-22 2014-05-01 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
US10851184B2 (en) 2014-08-22 2020-12-01 Cydex Pharmaceuticals, Inc. Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3544983A1 (de) * 1985-12-19 1987-06-25 Hoechst Ag Antimykotisch wirksamer nagellack
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5703079A (en) * 1993-12-21 1997-12-30 Schering Corporation Tetrahydrofuran antifungals
US5661151A (en) * 1993-12-21 1997-08-26 Schering Corporation Tetrahydrofuran antifungals
US6461622B2 (en) * 1994-09-07 2002-10-08 Johnson & Johnson Consumer Companies, Inc. Topical compositions
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US6106866A (en) * 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US5972381A (en) * 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
AU764001B2 (en) * 1998-05-29 2003-08-07 Skyepharma Canada Inc. Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
EP1027885B1 (en) * 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
WO2001056562A1 (en) * 2000-02-04 2001-08-09 Takeda Chemical Industries, Ltd. Stable emulsion compositions
AU2001255515A1 (en) * 2000-09-20 2002-04-02 Skyepharma Canada Inc. Stabilised fibrate microparticles
WO2002036203A2 (en) * 2000-11-02 2002-05-10 Influx, Inc. Azole containing compositions with enhanced antifungal activity
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
NZ528363A (en) * 2001-04-03 2005-04-29 Schering Corp Liquid suspensions of posaconazole ( SCH 56592 ) with enhanced bioavailability for treating fungal infections
WO2004026303A2 (en) * 2002-09-23 2004-04-01 Schering Corporation Use of posaconazole for the treatment of fungal infections
EP1694657A1 (en) * 2003-12-09 2006-08-30 Pfizer Inc. Compositions comprising an hiv protease inhibitor
AU2005249502A1 (en) * 2004-05-28 2005-12-15 Schering Corporation Particulate-stabilized injectable pharmaceutical compositions of posaconazole

Also Published As

Publication number Publication date
US20060009469A1 (en) 2006-01-12
WO2006130177A1 (en) 2006-12-07
TW200640459A (en) 2006-12-01
AR052162A1 (es) 2007-03-07

Similar Documents

Publication Publication Date Title
PE20061154A1 (es) Composiciones farmaceuticas inyectables estabilizadas con particulados de posaconazol
ES2531646T3 (es) Composiciones de emulsión farmacéuticas con bajo contenido de aceite que comprenden progestágeno
MX2021007794A (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
PE20060291A1 (es) Composiciones farmaceuticas inyectables de posaconazol con particulas estabilizadas
PE20080765A1 (es) Formas de dosificacion farmaceutica
BR112014006596A2 (pt) nanopartícula que encapsula uma pluralidade de nanocarreadores, composição, uso de uma nanopartícula, kit, sistema de entrega, processo para obter uma nanopartícula, e, processo de nanoaspersão para obter as nanopartículas
HK1208161A1 (en) Pharmaceutical nanoparticles showing improved mucosal transport
BR112014008255A2 (pt) composições antimicrobianas e métodos empregando as mesmas
WO2015152693A3 (ko) 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물
CO2017012670A2 (es) Unidad de dosificación orodispersable que contiene un componente estetrol
CO6650381A2 (es) Composiciones de pesticida de párticulas meso-dimensionadas con actividad mejorada
BR112012005969A2 (pt) forma de dosagem sólida oral contendo nanopartículas e processo de formulação da mesma usando gelatina de peixe
NO20073559L (no) Nanopartiklulaere tacrolimus-formuleringer
AR093106A1 (es) Silicato de zirconio microporoso para el tratamiento de la hipercalemia
NZ573555A (en) Nanoparticulate posaconazole formulations
CO2017007137A2 (es) Composición farmacéutica que comprende plasminógeno y usos de este
MX355330B (es) Formas cristalinas de compuestos terapeuticos y sus usos.
AR084318A1 (es) Composicion que comprende particulas de insecticida-cera
AR085527A1 (es) Una composicon farmaceutica para tratar una enfermedad en la cavidad oral que comprende rebamipida
MX2017009699A (es) Composicion de suspension oftalmica.
AR082155A1 (es) Formulacion antiseptica y desinfectante que tiene contenido de yodo reducido
MX383392B (es) Mezclas y formulaciones que comprenden una sal de alquil amonio de ácido etilendiaminotetraacético (edta).
AR072071A1 (es) Composiciones farmaceuticas mejoradas que contienen una droga antibiotico de fluoroquinolona
CY1112917T1 (el) Υγρες στοματικες συνθεσεις
GT201400027A (es) Acuosa suspensión concentrada que comprende un ácido sal de dodecilguanidina

Legal Events

Date Code Title Description
FC Refusal